E Slatopolsky
Overview
Explore the profile of E Slatopolsky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
255
Citations
3403
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mizobuchi M, Finch J, Martin D, Slatopolsky E
Kidney Int
. 2007 Jun;
72(6):709-15.
PMID: 17597697
Vascular calcification is associated with cardiovascular disease, the most common cause of death in chronic kidney disease (CKD). Patients with CKD are treated with vitamin D receptor activators (VDRAs); therefore,...
2.
Dusso A, Sato T, Arcidiacono M, Alvarez-Hernandez D, Yang J, Gonzalez-Suarez I, et al.
Kidney Int Suppl
. 2006 Jul;
(102):S8-11.
PMID: 16810310
Parathyroid hyperplasia is the cause of parathyroid gland enlargement in kidney disease (KD). Hypocalcemia, hyperphosphatemia, and vitamin D deficiency are critical contributors to the worsening of the hyperplastic parathyroid growth...
3.
Ritter C, Armbrecht H, Slatopolsky E, Brown A
Kidney Int
. 2006 Jun;
70(4):654-9.
PMID: 16807549
Active vitamin D compounds repress parathyroid hormone (PTH) gene transcription and block chief cell hyperplasia, making them integral tools in the treatment of secondary hyperparathyroidism in patients with chronic kidney...
4.
Joist H, Ahya S, Giles K, Norwood K, Slatopolsky E, Coyne D
Clin Nephrol
. 2006 May;
65(5):335-41.
PMID: 16724654
Background: Treatment of secondary hyperparathyroidism (SHPT) includes use of calcitriol (1,25D(3)) to suppress parathyroid hormone (PTH), but dosing of 1,25D(3) is limited by the development of hypercalcemia and a high...
5.
Cozzolino M, Lu Y, Finch J, Slatopolsky E, Dusso A
Kidney Int
. 2001 Dec;
60(6):2109-17.
PMID: 11737585
Background: High dietary phosphorus (P) worsens uremia-induced parathyroid (PT) hyperplasia through increases in the growth promoter transforming growth factor-alpha (TGF-alpha). In contrast, P restriction prevents PT hyperplasia by inducing the...
6.
Huang Z, Cheng S, Slatopolsky E
J Biol Chem
. 2001 Apr;
276(24):21351-8.
PMID: 11292824
Elevated levels of [Ca(2+)](o) in bone milieu as a result of the resorptive action of osteoclasts are implicated in promoting proliferation and migration of osteoblasts during bone remodeling. However, mitogenic...
7.
Dusso A, Pavlopoulos T, Naumovich L, Lu Y, Finch J, Brown A, et al.
Kidney Int
. 2001 Mar;
59(3):855-65.
PMID: 11231340
Background: The parathyroid (PT) hyperplasia induced by renal failure can be further enhanced by high dietary phosphate (P) or completely abolished by P restriction. To identify potential mechanisms mediating these...
8.
Slatopolsky E, Brown A, Dusso A
Am J Kidney Dis
. 2001 Feb;
37(1 Suppl 2):S54-7.
PMID: 11158862
Secondary hyperparathyroidism (SH) and hyperplasia of the parathyroid glands (PTG) are universal complications in patients with CRF. In early renal failure, reduction in serum calcitriol and moderate decreases in ionized...
9.
Delmez J, Kelber J, Norwood K, Giles K, Slatopolsky E
Clin Nephrol
. 2000 Nov;
54(4):301-8.
PMID: 11076106
Background: Calcitriol is widely used in conjunction with phosphorus-binders containing calcium to treat secondary hyperparathyroidism in dialysis patients. Its efficacy in patients with severe hyperparathyroidism is diminished, in part, due...
10.
Chertow G, Plone M, Dillon M, Burke S, Slatopolsky E
Clin Nephrol
. 2000 Nov;
54(4):295-300.
PMID: 11076105
Background: Secondary hyperparathyroidism and its effects on bone and viscera are among the most important complications of end-stage renal disease. Despite its ubiquity, little is known about the treated natural...